This article is more than 5 years old. Information may no longer be current.

Cognoptix receives $15 million to develop eye test to identify Alzheimer's

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Cognoptix announced that it has closed the first portion of a Series D round of financing for more than $15 million to develop the Sapphire II eye test to identify Alzheimer’s disease by utilizing a beta-amyloid signature.

The Sapphire II detects a specific fluorescent signature of ligand-marked A-beta in the supranucleus region of the human lens, according to the press release.

Sapphire II achieved a sensitivity of 85% and a specificity of 95% in differentiating 20 patients who were clinically diagnosed with probable Alzheimer’s disease from a group of 20 age-matched healthy volunteers in a phase 2 clinical trial, according to Cognoptix.

The Series D investment will fund the trial and the final stages of product development and allow Cognoptix to complete U.S. Food and Drug Administration registration.